<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954497</url>
  </required_header>
  <id_info>
    <org_study_id>C01367</org_study_id>
    <nct_id>NCT02954497</nct_id>
  </id_info>
  <brief_title>Pumps for Kids, Infants, and Neonates</brief_title>
  <acronym>PumpKIN</acronym>
  <official_title>Pumps for Kids, Infants, and Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthCore-NERI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jarvik Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthCore-NERI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the&#xD;
      investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility&#xD;
      trial will enroll 10 subjects at up to 7 sites in the US.&#xD;
&#xD;
      The primary objectives of this investigational device exemption (IDE) clinical investigation&#xD;
      are to assess the feasibility of using the Jarvik 2015 in pediatric patients with severe&#xD;
      heart failure who require mechanical circulatory support. Feasibility will be assessed by&#xD;
      evaluating the safety profile of the Jarvik 2015 device in eligible subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Feasibility</measure>
    <time_frame>30 days or transplant/recovery (whichever comes first)</time_frame>
    <description>To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint defined as transplant, recovery or 30 days of support</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days or transplant/recovery (whichever comes first)</time_frame>
    <description>To evaluate the protocol defined (INTERMACS version 5.0) serious adverse events on Jarvik 2015 support up to transplant, recovery or 30 days of support</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical, surgical, and clinical milestones assessed by feasibility milestones</measure>
    <time_frame>up to 180 days or transplant/recovery</time_frame>
    <description>To describe the technical, surgical and clinical feasibility by achieving specific technical, surgical, and clinical milestones that typically accompany a successful VAD support run</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pivotal Trial continuation assessed by exploratory primary and secondary endpoints</measure>
    <time_frame>12-months post-explant</time_frame>
    <description>To evaluate patients with respect to exploratory primary and secondary endpoints to inform the choice of appropriate primary and secondary endpoints for the pivotal trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events per patient days of VAD support</measure>
    <time_frame>180 days post-implant</time_frame>
    <description>The incidence rate of protocol-defined AEs (INTERMACS, version 5) per patient-day of VAD support up to the first 180 days post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events related to device</measure>
    <time_frame>180 days post-implant</time_frame>
    <description>Incidence rate of protocol-defined AEs possibly, probably, or definitely related to the device per day of mechanical circulatory support, up to the first 180 days post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological dysfunction</measure>
    <time_frame>180 days post-implant</time_frame>
    <description>The incidence of new neurological dysfunction up to 180 days post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Stroke Outcome Measure Neurological Exam (PSOM-NE) score (0 - 10 scale, higher = worse outcome)</measure>
    <time_frame>180 days and 12 months post-explant</time_frame>
    <description>Pediatric Stroke Outcome Measure-Neurological (PSOM-NE) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>King's Outcome Scale for Childhood Head Injury score (0 -5 scale, higher = worse outcome)</measure>
    <time_frame>180 days and 12 months post-explant</time_frame>
    <description>King's Outcome Scale for Childhood Head Injury (KOSCHI) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Stroke Recurrence and Recovery Questionnaire score (0 -10 scale, higher = worse outcome)</measure>
    <time_frame>180 days and 12 months post-explant</time_frame>
    <description>Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland Adaptive Behavior Scales score (scoring and scale different by domain)</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>Vineland Adaptive Behavior Scales (VABS II) measured at 12 months post-explant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life score (0-4 scale per domain, higher = worse outcome)</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>PedsQL20 measured at 180 days post-implant or immediately prior to explant and 12 months post-explant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Assist Device Quality of Life score (scoring and scale different per question)</measure>
    <time_frame>30 days, 90 days, 12 months post-explant</time_frame>
    <description>VAD QL measured at 30 and 90 days post-implant, and every 90 days thereafter, while on Jarvik 2015 VAD support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paralytics discontinuation</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>Time to discontinuation of paralytics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TPN discontinuation</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>Time to discontinuation of total parenteral nutrition (TPN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extubation</measure>
    <time_frame>30 days post-implant</time_frame>
    <description>Time to extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropic agents</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>Time to discontinuation of inotropic agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>30 days post-implant</time_frame>
    <description>Time to discontinuation of sedation such that subject is alert and interactive (e.g., engaging in age-appropriate play).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>Brain Magnetic Resonance Imaging (MRI) performed 12 months post-explant to assess for clinically silent neurologic injuries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in absence of severe neurological impairment</measure>
    <time_frame>180 days or tranplant/recovery (whichever comes first)</time_frame>
    <description>Overall survival in the absence of a severe neurologic impairment and in the absence of device failure at 180 days following VAD implant and meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Recovery (removal of VAD and alive at 30 days post-explant), Survival at 180 consecutive days of VAD support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in the absence of device failure</measure>
    <time_frame>180 days or tranplant/recovery (whichever comes first)</time_frame>
    <description>Overall survival in the absence of device failure but without regard for neurologic status, meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Survival to recovery (removal of Jarvik 2015 VAD and alive at 30 days post-explant), Survival at 180 consecutive days of Jarvik 2015 VAD support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 30 days post-implant</measure>
    <time_frame>30 days post-implant</time_frame>
    <description>Survival at 30 days post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 180 days post-implant</measure>
    <time_frame>180 days post-implant</time_frame>
    <description>Survival at 180 days post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 12 months post-explant</measure>
    <time_frame>12 months post-explant</time_frame>
    <description>Survival at 12 months post-explant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pump failure</measure>
    <time_frame>device explant</time_frame>
    <description>Time to first pump failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of pump failure</measure>
    <time_frame>device explant</time_frame>
    <description>Incidence rate of pump failures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first pump exchange</measure>
    <time_frame>device explant</time_frame>
    <description>Time to first pump exchanges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of pump exchange</measure>
    <time_frame>device explant</time_frame>
    <description>Incidence rate of pump exchanges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>180 days or immediately prior to explant</time_frame>
    <description>Proportion of subjects with a creatinine level below the ULNULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT level</measure>
    <time_frame>180 days or immediately prior to explant</time_frame>
    <description>Proportion of subjects with an alanine aminotransferase (ALT) level below the ULNULN</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pediatric Heart Failure</condition>
  <arm_group>
    <arm_group_label>Jarvik 2015 Device VAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New, experimental continuous flow VAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical placement of the Jarvik 2015 VAD</intervention_name>
    <description>The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.</description>
    <arm_group_label>Jarvik 2015 Device VAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Placement of Jarvik 2015 VAD</intervention_name>
    <description>Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.</description>
    <arm_group_label>Jarvik 2015 Device VAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Children must meet all of the following criteria:&#xD;
&#xD;
          1. Males and females within weight range 8 to 30 kg&#xD;
&#xD;
          2. Body surface area (BSA) 0.4 m2 to 1.0 m2&#xD;
&#xD;
          3. Cardiac Diagnosis:&#xD;
&#xD;
             a. Standard Cardiac Anatomy : Two-ventricle circulation, including cardiomyopathy,&#xD;
             repaired structural heart disease (e.g. anomalous left coronary artery from the&#xD;
             pulmonary artery [ALCAPA], aortic stenosis) or acquired heart disease (e.g.,&#xD;
             myocarditis, Kawasaki disease)&#xD;
&#xD;
          4. INTERMACS Profile 1 or 2 as evidenced by one or more of the following:&#xD;
&#xD;
               1. Inability to wean from extra-corporeal membrane oxygenation (ECMO) or other&#xD;
                  temporary circulatory support (TCS), OR&#xD;
&#xD;
               2. Inability to wean from mechanical ventilator support, OR&#xD;
&#xD;
               3. Inotrope-dependent, decompensated heart failure AND meet one or more of the&#xD;
                  following criteria within 48 hours prior to implant (unless otherwise noted)&#xD;
                  which is attributed to decompensated heart failure despite optimal medical&#xD;
                  therapy:&#xD;
&#xD;
             i. Urine output &lt;0.5 cc/kg/hour for 12hr within 48 hours ii. Creatinine level &gt;2 times&#xD;
             the ULN for age iii. Alanine aminotransferase (ALT) or total bilirubin result &gt;3 times&#xD;
             the ULN for age (either qualifies the patient) iv. Mixed venous oxygen saturation&#xD;
             (SvO2) &lt;55% (or arteriovenous oxygen difference of &gt;45%) in two repeated measurements&#xD;
             v. Acidosis: Base excess &gt;-5 in 2 or more measurements vi. Inability to tolerate&#xD;
             appropriate enteral calories as prescribed by a registered dietician d. Inability to&#xD;
             ambulate freely to participate fully in age-appropriate activities of daily living&#xD;
             (ADLs) and/or cardiac rehabilitation/physical therapy&#xD;
&#xD;
          5. LVAD support is intended for bridge-to transplant. Subject is listed for transplant or&#xD;
             eligible (i.e., no medical or surgical contraindications) to be listed for cardiac&#xD;
             transplant, United Network for Organ Sharing (UNOS) status 1A, or equivalent&#xD;
&#xD;
          6. Written consent of parent(s) or legally authorized representative (LAR) where&#xD;
             appropriate.&#xD;
&#xD;
        Children must not meet any of the following exclusion criteria within 48 hours prior to&#xD;
        device implant:&#xD;
&#xD;
          1. Known contraindication for systemic anticoagulation&#xD;
&#xD;
          2. Currently participating in an interventional trial whose protocol prevents effective&#xD;
             application of Jarvik 2015, potentially has an independent effect on trial endpoints,&#xD;
             or otherwise interferes with execution of the PumpKIN protocol&#xD;
&#xD;
          3. Stable inotrope dependence (INTERMACS profile 3)&#xD;
&#xD;
          4. Single ventricle anatomy&#xD;
&#xD;
          5. Presence of a mechanical heart valve&#xD;
&#xD;
          6. Unresolved malignancy&#xD;
&#xD;
          7. CPR with duration &gt;30 consecutive minutes within 48 hours prior to device implant or&#xD;
             CPR with uncertain neurological status prior to device implant&#xD;
&#xD;
          8. Renal dysfunction that is severe or, in the opinion of the investigator, irreversible&#xD;
&#xD;
          9. Hepatic dysfunction that is severe or, in the opinion of the investigator,&#xD;
             irreversible&#xD;
&#xD;
         10. Severe or irreversible pulmonary dysfunction&#xD;
&#xD;
         11. ECMO use for &gt;10 consecutive days&#xD;
&#xD;
         12. Unrepairable severe aortic insufficiency&#xD;
&#xD;
         13. Active, systemic infection unresponsive to antimicrobial therapy&#xD;
&#xD;
         14. Known cerebrovascular event within the past 30 days or uncertain neurological status&#xD;
&#xD;
         15. Severe right ventricular (RV) dysfunction or significant arrhythmia requiring&#xD;
             treatment with an RV assist device (RVAD) (i.e., biventricular assist device)&#xD;
&#xD;
         16. Unmanageable bleeding per judgment of the investigator&#xD;
&#xD;
         17. Ventricular dysfunction that is likely to recover (e.g. myocarditis, metabolic&#xD;
             myopathy where LV dysfunction is present solely with intermittent acidosis/crises).&#xD;
&#xD;
         18. Left ventricular end-diastolic dimension or left ventricular end-diastolic volume z&#xD;
             score of &lt; +2.5 end-diastolic dimension or ventricular end-diastolic volume z score of&#xD;
             &lt; +3.0&#xD;
&#xD;
         19. Left ventricular ejection fraction of &gt;35%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T Mahle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Atlanta, Emory University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Magnavita, MPH</last_name>
    <phone>6179723182</phone>
    <phone_ext>6179723182</phone_ext>
    <email>amagnavita@healthcore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rosenthal, MD</last_name>
      <email>davidnr@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirk Kanter, MD</last_name>
      <phone>404-785-6330</phone>
      <email>kkanter@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Flynn-Thompson, MD</last_name>
      <email>Francis.Fynn-Thompson@cardio.chboston.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Chai, MD</last_name>
      <phone>212-305-5975</phone>
      <email>pjc@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Morales, MD</last_name>
      <email>david.morales@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Davies, MD</last_name>
      <phone>214-456-5000</phone>
      <email>ryan.davies@utshouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iki Adachi, MD</last_name>
      <email>ixadachi@texaschildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ventricular assist device</keyword>
  <keyword>congenital heart disease</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Limited use data set will be made available through NHLBI after the conclusion of the trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

